Trials / Recruiting
RecruitingNCT06520488
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Agents in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-4642 | Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG |
Timeline
- Start date
- 2024-08-09
- Primary completion
- 2027-03-01
- Completion
- 2027-07-01
- First posted
- 2024-07-25
- Last updated
- 2025-09-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06520488. Inclusion in this directory is not an endorsement.